Houseman, Maja; Huang, Melody Ying-Yu; Huber, Markus; Staiger, Matthias; Zhang, Lan; Hoffmann, Anneliese; Lippuner, Christoph; Stüber, Frank (2022). Flow cytometry-based high-throughput RNAi screening for miRNAs regulating MHC class II HLA-DR surface expression. European journal of immunology, 52(9), pp. 1452-1463. Wiley 10.1002/eji.202149735
|
Text
Eur_J_Immunol_-_2022_-_Houseman_-_Flow_cytometry_based_high_throughput_RNAi_screening_for_miRNAs_regulating_MHC_class_II.pdf - Accepted Version Available under License Publisher holds Copyright. Download (4MB) | Preview |
Human leukocyte antigen-DR isotype (HLA-DR) is a major histocompatibility class II (MHC-II) cell surface receptor found on antigen-presenting cells (APCs) and plays a key role in initiating immune responses. In severely immunocompromised patients with conditions like sepsis, the number of HLA-DR molecules expressed on leukocytes is considered to correlate with infectious complications and patients' probability of survival. The underlying regulatory mechanisms of HLA-DR expression remain largely unknown. One probable path to regulation is through microRNAs (miRNAs), which have been implicated as regulatory elements of both innate and adaptive immune system development and function. In our study, flow cytometry-based high-throughput miRNA screening was performed in a stable HLA-DR-expressing human melanoma cell line, MelJuSo, for either up- or down-regulating miRNAs of the surface HLA-DR expression. By the end of the screening, the top ten up-regulators and top five down-regulators were identified, and both the HLA-DR protein and mRNA regulations were further verified and validated. In silico approaches were applied for functional miRNA-mRNA interaction prediction. The potential underlying gene regulations of different miRNAs were proposed. Our results promote the study of miRNA-mediated HLA-DR regulation under both physiological and pathological conditions, and may pave the way for potential clinical applications. This article is protected by copyright. All rights reserved.